London Healthtech Startup Digistain Named EIT Venture Award Finalist for AI Cancer Diagnostics Innovation

Digistain, a London-based healthtech startup, has been selected as one of nine finalists competing for the European Institute of Innovation and Technology’s prestigious 2026 Venture Award. The company will travel to Budapest on December 2, 2026, to present its innovations for a chance to win up to €50,000 in prize money.

Founded in 2020 by Dr. Hemmel Amrania, Digistain has developed an artificial intelligence-powered platform designed to analyse tumour samples and assess individual breast cancer risk. The technology aims to guide early chemotherapy decisions, offering clinicians data-driven insights to inform treatment strategies for cancer patients. The startup’s nomination came through EIT Health, one of the European Institute of Innovation and Technology’s dedicated innovation communities.

Recognition for European Innovation

The announcement of the nine finalists represents a significant milestone in the EIT’s annual awards programme, which celebrates breakthrough innovations across Europe’s startup ecosystem. Digistain’s selection underscores the growing prominence of AI-driven diagnostics in addressing critical healthcare challenges on the continent.

Martin Kern, Director of EIT, commented on the calibre of this year’s finalists, stating: “Our finalists demonstrate how their remarkable innovations can improve our lives while strengthening Europe’s competitiveness. It is no coincidence that they have achieved these results thanks to the support of dedicated innovation communities. We look forward to hearing their presentations at what promises to be an exciting final in Budapest on December 2.”

The statement highlights the role that structured innovation ecosystems play in nurturing competitive healthtech ventures, with EIT Health’s backing proving instrumental in Digistain’s pathway to the awards final.

Growing Opportunities in AI Healthcare

The inclusion of Digistain among the EIT’s finalist cohort reflects broader momentum in European healthtech development. AI-driven diagnostic platforms have emerged as a priority area for investment and support across the continent, with both public and private stakeholders recognising the potential for machine learning to improve cancer detection and treatment outcomes.

Digistain’s focus on breast cancer risk assessment and chemotherapy guidance positions the company within a wider movement towards personalised medicine. By leveraging artificial intelligence to analyse pathology samples, the platform aims to reduce clinical uncertainty and potentially improve patient outcomes through more targeted therapeutic interventions.

The December competition will bring together Europe’s most promising innovative ventures, offering visibility and validation within the broader startup and investor communities. For Digistain, the platform provides an opportunity to showcase its technology to a European audience and secure funding that could accelerate further development and market expansion.

The EIT’s recognition of Digistain demonstrates the continued strength of innovation pipelines across the European healthtech sector, particularly in emerging areas such as AI-powered diagnostics where European startups are building competitive advantages in both research and commercialisation.

Leave a Comment